What is the long-term trend for ANI Pharmaceuticals's increase (decrease) in prepaid expense?

Over 2 years (2022 to 2025), ANI Pharmaceuticals's increase (decrease) in prepaid expense has grown at a 150.9% compound annual growth rate (CAGR), from $798K to $5.02M.

ANI Pharmaceuticals ANIP Increase (Decrease) in Prepaid Expense

Increase (Decrease) in Prepaid Expense at other companies

Aurinia PharmaceuticalsAUPH

——

XER

Xeris Biopharma Holdings, Inc.XERS

——

Acadia PharmaceuticalsACAD

——

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's increase (decrease) in prepaid expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's increase (decrease) in prepaid expense?: ANI Pharmaceuticals (ANIP) reported increase (decrease) in prepaid expense of -$2.69M in Q1 2026.
How has ANI Pharmaceuticals's increase (decrease) in prepaid expense changed year-over-year?: ANI Pharmaceuticals's increase (decrease) in prepaid expense decreased by 168.1% year-over-year, from $3.95M to -$2.69M.
What is the long-term trend for ANI Pharmaceuticals's increase (decrease) in prepaid expense?: Over 2 years (2022 to 2025), ANI Pharmaceuticals's increase (decrease) in prepaid expense has grown at a 150.9% compound annual growth rate (CAGR), from $798K to $5.02M.